The molecular basis of covid-19 pathogenesis, conventional and nanomedicine therapy

29Citations
Citations of this article
136Readers
Mendeley users who have this article in their library.

Abstract

In late 2019, a new member of the Coronaviridae family, officially designated as “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2), emerged and spread rapidly. The Coronavirus Disease-19 (COVID-19) outbreak was accompanied by a high rate of morbidity and mortality worldwide and was declared a pandemic by the World Health Organization in March 2020. Within the Coronaviridae family, SARS-CoV-2 is considered to be the third most highly pathogenic virus that infects humans, following the severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV). Four major mechanisms are thought to be involved in COVID-19 pathogenesis, including the activation of the renin-angiotensin system (RAS) signaling pathway, oxidative stress and cell death, cytokine storm, and endothelial dysfunction. Following virus entry and RAS activation, acute respiratory distress syndrome develops with an oxidative/nitrosative burst. The DNA damage induced by oxidative stress activates poly ADP-ribose polymerase-1 (PARP-1), viral macrodomain of non-structural protein 3, poly (ADP-ribose) glycohydrolase (PARG), and transient receptor potential melastatin type 2 (TRPM2) channel in a sequential manner which results in cell apoptosis or necrosis. In this review, blockers of angiotensin II receptor and/or PARP, PARG, and TRPM2, including vitamin D3, trehalose, tannins, flufenamic and mefenamic acid, and losartan, have been investigated for inhibiting RAS activation and quenching oxidative burst. Moreover, the application of organic and inorganic nanoparticles, including liposomes, dendrimers, quantum dots, and iron oxides, as therapeutic agents for SARS-CoV-2 were fully re-viewed. In the present review, the clinical manifestations of COVID-19 are explained by focusing on molecular mechanisms. Potential therapeutic targets, including the RAS signaling pathway, PARP, PARG, and TRPM2, are also discussed in depth.

References Powered by Scopus

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

35213Citations
N/AReaders
Get full text

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

8802Citations
N/AReaders
Get full text

A new coronavirus associated with human respiratory disease in China

8324Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Molecular pathways involved in COVID-19 and potential pathway-based therapeutic targets

90Citations
N/AReaders
Get full text

Antibacterial and antiviral high-performance nanosystems to mitigate new SARS-CoV-2 variants of concern

54Citations
N/AReaders
Get full text

A Journey of Challenges and Victories: A Bibliometric Worldview of Nanomedicine since the 21st Century

27Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Kouhpayeh, S., Shariati, L., Boshtam, M., Rahimmanesh, I., Mirian, M., Esmaeili, Y., … Makvandi, P. (2021). The molecular basis of covid-19 pathogenesis, conventional and nanomedicine therapy. International Journal of Molecular Sciences, 22(11). https://doi.org/10.3390/ijms22115438

Readers over time

‘21‘22‘23‘24‘25015304560

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 26

55%

Researcher 14

30%

Lecturer / Post doc 5

11%

Professor / Associate Prof. 2

4%

Readers' Discipline

Tooltip

Medicine and Dentistry 22

55%

Biochemistry, Genetics and Molecular Bi... 8

20%

Nursing and Health Professions 6

15%

Pharmacology, Toxicology and Pharmaceut... 4

10%

Article Metrics

Tooltip
Social Media
Shares, Likes & Comments: 11

Save time finding and organizing research with Mendeley

Sign up for free
0